

## Tentative Agenda & Scientific Program

### Day 1 - WORKSHOPS: Wednesday June 3<sup>rd</sup>

George D. Behrakis Grand Hall/Creese Student Center, Drexel University, 3210 Chestnut St, Philadelphia, PA 19104. Street View: <https://maps.app.goo.gl/4UbTEi1KLqfVuRd8A>

10:30AM	<b>Registration</b> <i>(Continued all day)</i>	
12:00 – 13:00	<b>Grant writing session/NIH/RFAs</b> <b>Moderator: Fatah Kashanchi</b>	
13:00 – 15:00	<b>Workshop 1</b> <b>Public Health, Transmission &amp; Community Engagement</b> <i>(Leandro Sereno &amp; Damian Purcell)</i>	<b>Workshop 2</b> <b>Molecular Virology and Immunopathogenesis</b> <i>(Chairs: Edward Harhaj &amp; Amanda Panfil)</i>
	<p style="text-align: center;"><b>HTLV-1 Pre-Exposure Prophylaxis Working Group</b> Fabiola Martin, Australia</p> <p style="text-align: center;"><b>Brasil Saudável”, A bold agenda to eliminate HTLV - a Public Health Problem</b> Pamela Gaspar, Brazil</p> <p style="text-align: center;"><b>Ensuring blood safety, and interrupting HTLV transmission</b> Sheila O’Brien, Univ Ottawa</p> <p style="text-align: center;"><b>Public health impact of HTLV in vulnerable populations and geographic areas in Peru</b> Eduardo Gotuzzo, Peru</p> <p style="text-align: center;"><b>HTLV-1 mother-to-child transmission</b> Andrea Thoma-Kress, Germany</p> <p style="text-align: center;"><b>Status of HTLV-1 in Aboriginals communities</b> Lloyd Einsiedel, Australia</p> <p style="text-align: center;"><b>HTLV challenges and opportunities in the international public health agenda</b> Josh Anzinger</p>	<p style="text-align: center;"><b>Genetic landscape and clonal evolution of ATLL</b> Aileen Rowan (UK)</p> <p style="text-align: center;"><b>HTLV-1 particle assembly and transmission</b> Louis Mansky, USA</p> <p style="text-align: center;"><b>Mechanisms of latent HTLV-1 infection, clonal evolution and genetic landscape of ATLL</b> Yorifumi Satou, Japan</p> <p style="text-align: center;"><b>The role of transcription regulation in the life cycle of HTLV-1 and BLV</b> Luc Willems, Belgium</p> <p style="text-align: center;"><b>HTLV-1-induced innate dysfunction</b> Helene Dutartre, France</p> <p style="text-align: center;"><b>Molecular Virology of HTLV</b> Zoom - Benoit Barbeau, Canada</p> <p style="text-align: center;"><b>Pathogenesis of HAM/TSP</b> Christopher Itoh</p>
15:00 – 15:30	<b>Coffee Break</b>	

<p>15:30 – 17:30</p>	<p style="text-align: center;"><b>Workshop 3</b> <b>HTLV epidemiology, phylogenetics, and diagnostics</b> <i>(Graham Taylor &amp; Robert Harrod)</i></p> <p><b>Standardizing molecular diagnosis of HTLV infections</b> Philippa Hetzel, Australia</p> <p><b>Contributions of Molecular Epidemiology and Sequence Analysis to HTLV-1 Research</b> Philippe Afonso, France</p> <p><b>Diagnosis of HTLV infections in early life</b> Carolina Rosadas, UK</p> <p><b>Pathogenesis of HAM/TSP and Its Implications for Drug Discovery</b> Yoshi Yamano, Japan</p> <p><b>Molecular epidemiology of HTLV-1/2 in the Americas</b> Ricardo Ishak, Brazil</p> <p><b>IRVA Africa meeting, safety of blood transfusions in Africa and the need to inform public policy</b> Jean-Claude Twizere</p> <p><b>Revision of the Japanese clinical practice guideline for HTLV-1– Associated Myelopathy</b> Tomoo Sato, Japan</p>	<p style="text-align: center;"><b>Workshop 4</b> <b>Preclinical models, clinical guidelines, and trials</b> <i>(Luis Malpica &amp; R. Alejandro Sica)</i></p> <p><b>HTLV animal models (ATLL &amp; HAM/TSP)</b> Patrick Green, USA</p> <p><b>US National Cancer Research Network (NCCN) guidelines</b> Steven Horwitz, USA</p> <p><b>Targeting Epigenetic and Other Pathways in ATLL</b> Toshiki Watanabe, Japan</p> <p><b>Evidence-based treatment recommendations for ATLL</b> Lucy Cook, London</p> <p><b>Advances in Stem Cell Transplant for ATLL</b> Ali Bazarbachi, Lebanon</p> <p><b>Current &amp; emerging therapeutic strategies for ATLL in USA</b> Juan Carlos Ramos, USA</p> <p><b>Overview of Current clinical trials data</b> Olivier Hermine, France</p>
<p>17:30 - 19:00</p>	<p style="text-align: center;"><b>Welcome Reception</b> Constantine N. Papadakis Integrated Sciences Building (PISB) 3245 Chestnut St, Philadelphia, PA 19104 Street View: <a href="https://maps.app.goo.gl/nY6y47EQ9kHSnt2a8">https://maps.app.goo.gl/nY6y47EQ9kHSnt2a8</a></p>	

**Day 2 - Thursday June 4<sup>th</sup>**

George D. Behrakis Grand Hall/Creese Student Center, Drexel University, 3210 Chestnut St, Philadelphia, PA 19104.

08:30 – 09:30	<b>Opening Ceremony</b>
09:30- 10:00	<b>Coffee Break</b>
10:00 – 11:30	<p style="text-align: center;"><b>Symposium 1 - Host pathogen interaction</b> <b>Chairs: Arnold Rabson and Lishomwa Ndhlovu</b></p> <p style="text-align: center;"><b>10:00 – 10:15 – Investigating the role of PP2A-B56 in establishing HTLV-1 infection</b> Goedele Maertens, Imperial College London, London, United Kingdom</p> <p style="text-align: center;"><b>10:15 – 10:27 - CRM1 hijacking by HTLV-1 Rex reprograms the UPF1 helicase from antiviral to proviral functions</b> Vincent Mocquet, INSERM, Lyon, France</p> <p style="text-align: center;"><b>10:27 – 10:39 - Hijacking antiviral defense: a restriction factor that promotes clonal expansion in adult T-cell leukemia</b> Alexis Fontaine, University of Liege, Liege, Belgium</p> <p style="text-align: center;"><b>10:39 – 10:51 - Non-random organization of provirus-host 3D chromatin interactions across HTLV-1-infected clones</b> Mateo Bazire, Laboratoire de Biologie et Modélisation de la Cellule (LBMC), Ecole Normale Supérieure de Lyon, France</p> <p style="text-align: center;"><b>10:51 – 11:03 - Human breast milk prevents acid-induced cell death of HTLV-1 infected cells, enhances release of infectious virus and modulates the viral biofilm</b> Franziska Wittdorf, Harald zur Hausen Institute of Virology, Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany</p> <p style="text-align: center;"><b>11:03 – 11:15 - HTLV-1 Tax induces PINK1-Parkin-dependent mitophagy to mitigate activation of the cGAS-STING pathway</b> Edward Harhaj, Penn State College of Medicine, Hershey, USA</p> <p style="text-align: center;"><b>11:15 – 11:27 - Dendritic Cells Pulsed with HAM/TSP Exosomes Sensitize CD4 T Cells to Enhance HTLV-1 Infection, Induce Helper T-Cell Polarization, and Decrease Cytotoxic T-Cell Response</b> Thomas Premeaux, Weill Cornell Medicine &amp; Drexel Medicine, USA</p>

<p>11:30 – 13:00</p>	<p style="text-align: center;"><b>Symposium 2 – Viral Proteins and Molecular Biology</b> <b>Chairs: Jianping Li and Louis Mansky</b></p> <p><b>11:30 – 11:45 - Structural Basis of Antibody Recognition of the HTLV Envelope</b> Tongqing Zhou, National Institute of Allergy and Infectious Diseases, Bethesda, USA</p> <p><b>11:45 – 11:57 - Identification of key HTLV-1 integrase residues for catalysis, host factor binding, and intasome formation</b> Aaron Mamane-Logsdon, Imperial College London, London, United Kingdom</p> <p><b>11:57 – 12:09 - Small-molecule modulators of BLV and HTLV proteases: from enzymatic screening to antiviral activity</b> Camila Sagasti, Institut Pasteur de Montevideo, Montevideo, Uruguay Facultad de Medicina, UdelaR, Montevideo, Uruguay</p> <p><b>12:09 – 12:21 - HTLV-1C p16 protein contributes to virus production and dissemination</b> Cynthia Pise-Masison, National Cancer Institute, Bethesda, USA</p> <p><b>12:21 – 12:33 - Whole genome HTLV-1 amplification using a simplified long-fragment polymerase chain reaction workflow optimized for next-generation sequencing</b> Felice Deminco, Professor Edgard Santos University Hospital, Salvador, Brazil</p> <p><b>12:33 – 12:45 –PRMT5 regulates HTLV-1 p30 stability and cell cycle progression</b> Bethany Pepple, The Ohio State University, Columbus, USA</p> <p><b>12:45 – 12:57 - Characterisation of proviral mutation diversity in HTLV-1-infected clones</b> Anat Melamed, Imperial College London, London, United Kingdom</p>
<p>13:00 – 14:00</p>	<p><b>Boxed Lunch</b></p>
<p>14:00 – 15:00</p>	<p><b>Keynote Lecture</b> <b>Chimeric Antigen Receptor T-cell Immunotherapy for T-cell Malignancies</b> Dr. Marco Ruella, MD CAR-T Therapy against Leukemia and Lymphoma Center for Cellular Immunotherapies, University of Pennsylvania (PennMedicine), Philadelphia, PA, USA</p>
<p>15:00 – 18:00</p>	<p><b>Poster Session &amp; Vendor exhibits</b> <b>(Papadakis integrated science building atrium)</b></p>
<p>18:00</p>	<p><b>IRVA EC Board Meeting/Free evening for rest</b></p>

**Day 3 – Friday June 5<sup>th</sup>**

Pennsylvania Convention Centre, 1101 Arch Street.

Enter through the 12th Street & West Arch entrance, right across the famous Reading Terminal Market/Panera Bread

08:00 – 08:30	<b>Morning Tea &amp; Coffee</b>
08:30 – 10:10	<p style="text-align: center;"><b>Symposium 3 - Inflammation and HAM/TSP</b> <b>Chairs: Steve Jacobsen and Fatah Kashanchi</b></p> <p><b>08:30 – 08:45 - T-cell exhaustion and high Tim-3 expression defines HTLV-1c infection and pulmonary disease</b> Ashley Hirons, Doherty Institute, Melbourne, Australia University of Melbourne, Melbourne, Australia</p> <p><b>08:45 – 08:57 - Senescence-driven inflammaging in HTLV-1 Infection: a multi-omics in vivo and in vitro signature</b> Johan Van Weyenbergh, KU Leuven, Leuven, Belgium</p> <p><b>08:57 – 09:09 - Transcriptional reprogramming in immune cells of HTLV-1 asymptomatic carriers and HAM/TSP patients following antiretroviral therapy</b> Sai Chaitanya Rajendra Gaekwar, Drexel Medicine, Philadelphia, USA</p> <p><b>09:09 – 09:21 - Cognitive Impairment associated with HTLV-1 infection: A case series with neuropsychological and advanced neuroimaging findings.</b> Billy McBenedict, Fluminense Federal University, Niteroi, Brazil</p> <p><b>09:21 – 09:33 - Tyrosine kinase inhibitors induce apoptosis in HTLV-1-infected T cells from HAM/TSP patients via Bim</b> Daisuke Kodama, Kagoshima University, Kagoshima City, Japan</p> <p><b>09:33 – 09:45 - Elucidating the relationship between neuroinflammation and brain white matter lesions in HTLV-1 infection</b> Marzia Puccioni-Sohler, Univesidade Federal do Estado do Rio de Janeiro (UNIRIO), Rio de Janeiro, Brazil Univesidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil</p> <p><b>09:45 – 09:57 - HTLV-1 associated myositis: A case series</b> Michael Wride, Imperial College Healthcare NHS Trust, London, United Kingdom</p> <p><b>09:57 – 10:09 - Single cell analysis of infected T cells from HAM/TSP patients</b> Saiful Islam, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan</p>
10:10 – 10:40	<b>Coffee Break</b>

<p>10:40 – 12:35</p>	<p style="text-align: center;"><b>Symposium 4 – Epidemiology/Diagnosis</b> <b>Chairs: Fernanda Grassi and Bobby Brooke Herrera</b></p> <p><b>10:40 – 10:55 - Comparison of clinical features and outcomes of adult T-cell leukemia/lymphoma across world regions: An international retrospective cohort study</b> Bryan Valcarcel, MD Anderson, Texas, USA</p> <p><b>10:55 – 11:07 - Population-based patterns of adult T-Cell leukemia/lymphoma in the United States</b> Paulo Pinheiro, University of Miami School of Medicine, Miami, USA</p> <p><b>11:07 - 11:19 - A cross-sectional view of HTLV-1 infection across pediatric, adult, and pregnant populations in an endemic region of Colombia</b> Juan P. Rojas-Hernández, Universidad del Valle, Cali, Colombia Universidad Libre seccional, Cali, Colombia Universidad San Martín, Cali, Colombia Pontificia Universidad Javeriana, Cali, Colombia</p> <p><b>11:19 – 11:31 - Prevalence of HTLV-1 infection among family members of people living with the virus: A systematic review and meta-analysis</b> Greice Carolina Santos da Silva, Oswaldo Cruz Foundation, Gonçalo Moniz Institute, Salvador, Brazil Imperial College London, London, United Kingdom</p> <p><b>11:31 – 11:43 - Quantification of HTLV-proviral load in whole blood and dried blood spots: an alternative to peripheral blood mononuclear cells</b> Momoko Usui, Imperial College London, London, United Kingdom</p> <p><b>11:43 – 11:55 - Evaluation and comparison of HTLV-1 proviral load using different methods</b> Gabriel Franco, Federal University of Bahia, Salvador, Brazil</p> <p><b>11:55 – 12:07 - HTLV-I family cluster with varied outcomes and a potential exposure-related HTLV-I seroindeterminate status</b> Jessica Cuenca-Iglesias, Instituto de Medicina Tropical “Alexander von Humboldt” (IMTAvH), Universidad Peruana Cayetano Heredia, Lima, Peru</p> <p><b>12:07 – 12:19 - Improving access to and quality of Molecular Testing for HTLV globally</b> Mirna Biglione, CONICET–Universidad de Buenos Aires, Buenos Aires, Argentina</p> <p><b>12:19 – 12:31 - Prevalence of Metabolic Syndrome and its components in HTLV positive individuals: A 10-year follow-up</b> Samaneh Abolbashari, Mashhad University of Medical Sciences, Mashhad, Islamic Republic of Iran</p>
<p>12:35 – 13:35</p>	<p style="text-align: center;"><b>Lunch – open</b></p>

<p>13:35 – 15:15</p>	<p style="text-align: center;"><b>Symposium 5 – Animal models</b> <b>Chairs: Patrick Green and Zafar Khan</b></p> <p style="text-align: center;"><b>13:35 – 13:50 - DTG use is associated with sustained decrease in HTLV-1 proviral load, that persists after 6 months of therapy interruption</b> Maria Arriaga, Federal University of Bahia, Salvador, Brazil</p> <p style="text-align: center;"><b>13:50 – 14:02 - Contribution to lung inflammation of genetic determinants in the HTLV-1C envelope</b> Genoveffa Franchini, National Cancer Institute, Bethesda, USA</p> <p style="text-align: center;"><b>14:02 – 14:14 - Efficient induction of anti-HTLV-1 neutralizing antibodies by immunization with LNP-mRNA expressing a membrane-anchored Env SU trimer</b> Hiroshi Ishii, National Institute of Infectious Diseases, Japan Institute for Health Security, Tokyo, Japan</p> <p style="text-align: center;"><b>14:14 – 14:26 - Combination antiretroviral therapy and MCL-1 inhibition mitigate HTLV-1 infection in vivo</b> Marcel Doerflinger, The Walter and Eliza Hall Institute of Medical Research, Parkville, Australia</p> <p style="text-align: center;"><b>14:26 – 14:38 - HTLV-1c Integration Rewires Host Nuclear Architecture and Enhancer Regulation in Infected T-Lymphocytes</b> ZOOM - Natasha Jansz, The Doherty Institute - University of Melbourne, Melbourne, Australia</p> <p style="text-align: center;"><b>14:38 – 14:50 - A small polypeptide encoded by antisense long non-coding RNAs mediates bovine leukemia virus replication</b> Thomas Jouant, University of Liege, Gembloux, Belgium</p> <p style="text-align: center;"><b>14:50 – 15:02 - HTLV-1 Hbz is a central determinant of viral persistence and oncogenic clonal expansion</b> Cameron Phelps, The Ohio State University, Columbus, USA</p> <p style="text-align: center;"><b>15:02 – 15:14 - Loss of viral enhancer and viral CTCF binding site impairs Hbz expression and HTLV-1 persistence</b> Amanda Panfil, The Ohio State University, Columbus, USA</p>
<p>15:15- 15:45</p>	<p style="text-align: center;"><b>Coffee Break</b></p>

<p>15:45 – 17:40</p>	<p style="text-align: center;"><b>Symposium 6 – ATLL (General)</b> <b>Chairs: Pierluigi Porcu and Lucy Cook</b></p> <p><b>15:45 – 16:00 – Glucose dynamics predict Post-Transplant Relapse in ATL, revealing broad metabolic reprogramming confirmed by multi-cohort cross-omics analysis</b> Kritika Subramanian, Rega Institute for Medical Research, KU Leuven, Leuven, Belgium Albert Einstein College of Medicine, Bronx, USA</p> <p><b>16:00 – 16:12 - Towards the validation of the Viral Clonality Evenness (VCE) index: a novel prognostic biomarker for adult T-cell leukemia</b> Anne-Sophie Reuter, GIGA, University of Liège, Liège, Belgium</p> <p><b>16:12 – 16:24 - Utility of flow cytometry for prognostic prediction in adult T-cell leukemia-IDrymphoma</b> Shigeo Fuji, Osaka International Cancer Institute, Osaka, Japan</p> <p><b>16:24 – 16:36 - EP300 deficiency leads to chronic replication stress driven aggressive Adult T-cell leukemia/lymphoma</b> Advaita Madireddy, Rutgers University, New Brunswick, USA</p> <p><b>16:36 – 16:48 - Genome-wide histone code remodelling in ATL and HAM/TSP</b> Haozheng Liao, The University of Tokyo, Japan</p> <p><b>16:48 – 17:00 - Tax is expressed in uncultured CD7-/CADM1+ primary ATL cells and is critical for ATL survival</b> Rita Hleihel, American University of Beirut, Faculty of Medicine, Beirut, Lebanon</p> <p><b>17:00 – 17:12 - Characterizing the Function Role of FOXO3 and its Clinical Implications in HTLV-1 Related Adult T-cell Leukemia-lymphoma</b> Georgios Pongas, Department of Medicine, Division of Hematology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, USA</p> <p><b>17:12 – 17:24 - IRF4 drives inflammasome and suppresses pyroptosis in ATLL</b> Daniel Rauch, Washington University, St Louis, USA</p> <p><b>17:24 – 17:36 - The role of EP300 in North American adult T-cell leukemia/lymphoma: downstream effector and therapeutic opportunity</b> Shiang-Jie Yang, Albert Einstein College of Medicine, New York, USA</p>
<p>18:00</p>	<p><b>HTLV Walk to dinner location, Moshulu Restaurant near Penn’s lending</b></p>

**Day 4 - Saturday June 6<sup>th</sup>**

Pennsylvania Convention Centre, 1101 Arch Street.

Enter through the 12th Street & West Arch entrance, right across the famous Reading Terminal Market/Panera Bread

08:00	<b>Morning Tea &amp; Coffee</b>
08:30 – 10:25	<p style="text-align: center;"><b>Symposium 7 – Therapeutic/ATLL</b> <b>Chairs: Juan C. Ramos and Vidyasagar Koduri</b></p> <p><b>08:30– 08:45 – First-in-Human CD70-Directed Allogeneic CAR T-Cell Therapy for HTLV-1 ATLL: Durable Responses and Molecular Evolution in the COBALT-LYM Trial</b> R. Alejandro Sica, Montefiore Medical Center, NYC, USA</p> <p><b>08:45 – 08:57 - Immune evasion via the NKG2A–HLA-E axis and its potential as a novel immunotherapeutic target in adult T-cell leukemia-lymphoma (ATL)</b> Takahisa Nakamura, Kumamoto University, Kumamoto, Japan</p> <p><b>08:57 – 09:09 - Role of a unique subset of cytolytic T cells in clinical response in the belinostat trial with zidovudine plus interferon for ATLL</b> B. Hilda Ye, Albert Einstein College of Medicine, New York, USA</p> <p><b>09:09 – 09:21 - Kromastat, a Polymer Nanoparticle of Class 1 Selective HDAC Inhibitor, Demonstrates Marked Activity in Adult T Cell Leukemia/Lymphoma</b> Rana Mhaidly, American University of Beirut, Beirut, Lebanon</p> <p><b>09:21 – 09:33 - Overcoming Adult T-Cell Leukemia/Lymphoma Survival Pathway with mTORC1 Blockade and BH3-Mimetics</b> Arezoo Darbandi &amp; Donna D'Agostino, Veneto Institute of Oncology IOV–IRCCS, Italy</p> <p><b>09:33 – 09:45 - Venetoclax-Based Therapeutic Strategies in Relapsed/Refractory North American Adult T-Cell Leukemia/Lymphoma</b> Ankit Tanwar, Albert Einstein College of Medicine, New York, USA</p> <p><b>09:45 – 09:57 - Adult T-cell Leukaemia/Lymphoma Outcomes in the UK in 2025</b> Anna Weatherill, Imperial College London, London, United Kingdom Imperial College Healthcare NHS Trust, London, United Kingdom</p> <p><b>09:57 – 10:09 - Immunological biomarkers in people with HTLV-1 treated with Dolutegravir</b> Carlos Brites, Federal University of Bahia, Salvador, Brazil</p> <p><b>10:09 – 10:21 – Long-term efficacy and safety of bexarotene in Japanese patients with adult T-cell leukemia-lymphoma: results from a phase II extension study (B-1901)</b> Kentaro Yonekura, Imamura General Hospital, Kagoshima, Japan</p>

10:25 – 10:50	<b>Coffee Break</b>
10:50 – 12:30	<p style="text-align: center;"><b>Symposium 8 – Policy/social impact/stigma Chairs: Goedele Maertens &amp; Carol Rosadas</b></p> <p><b>10:50 – 11:05 - HTLV in Brazil: Recent advances in national policies for surveillance, antenatal care, and the elimination of vertical transmission</b> Pâmela Gaspar, Department of HIV, AIDS, Tuberculosis, Viral Hepatitis, and Sexually Transmitted Infections, Secretariat for Health and Environmental Surveillance, Ministry of Health of Brazil, Brasília, Brazil</p> <p><b>11:05 – 11:17 - From invisibility to public policy: integrating HTLV into Brazil’s vertical transmission elimination certification process</b> Cristiano Francisco, General Coordination for Surveillance of Sexually Transmitted Infections, Department of HIV/AIDS, Tuberculosis, Viral Hepatitis and Sexually Transmitted Infections, Secretariat of Health Surveillance and Environment, Ministry of Health, Brasilia, Brazil</p> <p><b>11:17 – 11:29 - The HTLV Brazil Health Education Initiative: Multiple strategies for science communication and health education on HTLV and associated diseases</b> Clarice N Lins de Moraes, Oswaldo Cruz Foundation- Fiocruz, Recife, PE, Brazil</p> <p><b>11:29 – 11:41 - A community-based partnership to assess knowledge about HTLV-1 and ATLL and perceptions about research among an at-risk population in Philadelphia</b> Sean Reilly, Sidney Kimmel Comprehensive Cancer Center, Thomas Jefferson University Hospital, Philadelphia, USA</p> <p><b>11:41 – 11:53 - Strengthening Public Health Through HTLV-1 Surveillance: A Perspective on Seychelles’ Emerging Response</b> Louine Morel, Seychelles Ministry of Health, Victoria, Seychelles</p> <p><b>11:53 – 12:05 - Global disparities in HTLV-1 research and response: A unique focus on Caribbean and Polynesian/Japanese and Caribbean populations</b> Ryan Hoffmann, Drexel University College of Medicine, Philadelphia, USA</p> <p><b>12:05 – 12:17 - Innovation and Health Cooperation to Strengthen Molecular Diagnosis of HTLV in the Brazilian Unified Health System (SUS)</b> Renata Olivia Gadelha Romero, Rio Grande do Norte State Health Department, Natal, RN, Brazil</p> <p><b>12:17 – 12:29 - Strengthening community engagement to advance HTLV public policies in Brazil: from invisibility to national representation</b> Mayra Gonçalves Aragón, Department of HIV, AIDS, Tuberculosis, Viral Hepatitis, and Sexually Transmitted Infections, Secretariat for Health and Environmental Surveillance, Ministry of Health of Brazil, Brasília, Brazil</p>
12:30 – 13:30	<p><b>Closing Ceremony / Vote of Thanks</b> <b>Next Conference</b> <b>IRVA AGM, Announcements &amp; Awards</b></p>